

JC07 Rec'd PCT/PTO 13 DEC 2001

Form PTO 1390, U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 5-93)		ATTORNEY'S DOCKET NUMBER B45187
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>10/018704</b>
INTERNATIONAL APPLICATION NO PCT/EP00/05841	INTERNATIONAL FILING DATE 23 June 2000	PRIORITY DATE CLAIMED 29 June 1999
TITLE OF INVENTION VACCINE		
APPLICANT(S) FOR DO/EO/US Joe COHEN, Nathalie GARCON, and Gerald VOSS		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11. to 16. below concern other document(s) or information included:**

11. ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98; and Form PTO-1449.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☒ Please amend the specification by inserting before the first line the sentence: This is a 371 of International Application PCT/EP00/05841, filed June 23, 2000, which claims benefit from the following Provisional Application: GB 9915204.3, filed June 29, 1999.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ An Abstract on a separate sheet of paper.
19. ☒ Other items or information: Sequence Listing, Statement to Support, Diskette


10018704 1031702  
**531 Rec'd PCT.** 13 DEC 2001

US APPLICATION NO. (if known see 37 CFR 1.50) <b>10/018704</b>		INTERNATIONAL APPLICATION NO PCT/EP00/05841		ATTORNEYS DOCKET NO. B45187	
20. <input checked="" type="checkbox"/> The following fees are submitted:				<b>CALCULATIONS PTO USE ONLY</b>	
<b>Basic National Fee (37 C.F.R. 1.492(a)(1)-(5)):</b>					
Search Report has been prepared by the EPO or JPO .....\$890.00					
International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) .....\$710.00					
No International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....\$740.00					
Neither International Preliminary Examination Fee (37 CFR 1.492) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$1,040.00					
International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$100.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$890.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<b>\$0.00</b>	
Claims	Number Filed	Number Extra	Rate		
Total claims	<b>12 - 20 =</b>	<b>0</b>	<b>0 x \$18.00</b>	<b>\$0.00</b>	
Independent claims	<b>2 - 3 =</b>	<b>0</b>	<b>0 x \$84.00</b>	<b>\$0.00</b>	
Multiple dependent claims (if applicable)			<b>+ \$280.00</b>	<b>\$0.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$890.00</b>	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				<b>\$</b>	
<b>SUBTOTAL =</b>				<b>\$890.00</b>	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)) +				<b>\$</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$890.00</b>	
				Amount to be refunded	\$
				charged	\$

- a. ☐ A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 19-2570 in the amount of **\$890.00** to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2570. A duplicate copy of this sheet is enclosed.
- d. ☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extension of time relating to this application (37 CFR 1.136 (a)(3)).

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

**SEND ALL CORRESPONDENCE TO:**  
**GLAXOSMITHKLINE**  
 Corporate Intellectual Property - UW2220  
 P.O. Box 1539  
 King of Prussia, PA 19406-0939  
 Phone (610) 270-5024  
 Facsimile (610) 270-5090

  
 SIGNATURE  
 Zoltan Kerekes  
 NAME  
 38,938  
 REGISTRATION NO.

10/018704  
531 Rec'd PCT/77 13 DEC 2001

PATENT  
ATTORNEY'S DOCKET NUMBER B45187

TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE  
(DO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

---

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP00/05841	23 June 2000	29 June 1999

---

TITLE OF INVENTION  
VACCINE

---

APPLICANT(S) FOR DO/US  
Joe COHEN, Nathalie GARCON, and Gerald VOSS

---

BOX PCT  
Assistant Commissioner for Patents  
Washington, D.C. 20231  
ATTENTION: DO/US

---

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Transmittal Letter, Form PTO 1390 and the papers indicated as being transmitted therewith, and Post Card are being deposited with the United States Postal Service on this date December 13, 2001 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV000522470US addressed to the:  
Assistant Commissioner for Patents, Washington, D.C. 20231

Elsa Matos  
(Typed or printed name of person mailing paper)

Elsa Matos  
(Signature of person mailing paper)



20462

PATENT TRADEMARK OFFICE



10018704.030702 PCT  
JC05 Rec'd PCT/PTO 18 APR 2002  
#9  
5630  
CL

**"EXPRESS MAIL CERTIFICATE"**

"EXPRESS MAIL" MAILING LABEL NUMBER EV056712470US  
DATE OF DEPOSIT: APRIL 18, 2002

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES  
POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10  
ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO:

THE ASSISTANT COMMISSIONER FOR PATENTS,  
BOX SEQUENCE, PO BOX 2327, ARLINGTON, VA 22202.  
NAME OF PERSON MAILING PAPER OR FEE



(TYPE OR PRINT)  
SIGNATURE

*Kathy Taylor*  
*Kathy Taylor*

Attorney Docket No.: B45187

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Cohen, et al.

April 18, 2002

Serial No.: 10/018,704

Group Art Unit: Not Yet Assigned

Filing Date: December 13, 2001

Examiner: Not Yet Assigned

For: VACCINE

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE  
WITH 37 CFR §§ 1.821 THROUGH 1.825**

**BOX SEQUENCE**

Assistant Commissioner for Patents  
PO Box 2327  
Arlington, VA 22202

- ( X ) I hereby state that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with **37 CFR §1.821(c)** and **(e)**, respectively, are the same.
- ( X ) I hereby state that the submission filed in accordance with **37 CFR §1.821 (g)** does not include new matter.
- ( ) I hereby state that the submission filed in accordance with **37 CFR §1.821 (h)** does not include new matter or go beyond the disclosure in the international application as filed.
- ( ) I hereby state that the amendments, made in accordance with **37 CFR §1.825 (a)**, included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages \_\_\_\_\_. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- ( ) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.

- 2 -

Serial No.: 10/018,704  
Group Art Unit No.: Not Yet Assigned

( ) I hereby state that the substitute copy of the computer readable form,  
submitted in accordance with **37 CFR §1.825(d)**, is identical to that originally  
filed.

Respectfully submitted,



Stephen Venetianer  
Attorney for Applicants  
Registration No. 25,659

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5024  
Facsimile (610) 270-5090  
N:\zkapps\b45187\Sequence Listing Transmittal 2.doc

3.001137011.0307032  
"EXPRESS MAIL CERTIFICATE"  
"EXPRESS MAIL" MAILING LABEL NUMBER EV000522470US  
DATE OF DEPOSIT 13 December 2001

10/018704  
13 DEC 2001

Attorney Docket No. B45187

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Cohen, et al. 13 December 2001  
Int'l. App. No.: PCT/EP00/05841 Group Art Unit: Not Yet Assigned  
Int'l. Filing Date: 23 June 2000 Examiner: Unknown  
For: VACCINES

Assistant Commissioner for Patents  
Box PCT  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Preliminary to the examination of this application, applicants respectfully request amendment of the above-identified application as follows:

**IN THE CLAIMS:**

Please delete claims 1-12.  
Please add new claims 13-24.

13. A composition for raising an immune response comprising a malaria antigen and an immunostimulatory CpG oligonucleotide.
14. A composition as claimed in claim 13 wherein the antigen is selected from the group of malaria antigens consisting of RTS, RTS\*, TRAP and immunologically equivalent derivatives thereof.
15. A composition as claimed in claim 13 wherein the vaccine comprises TRAP or immunologically equivalent derivative and one of RTS or RTS\*.
16. A composition as claimed in claim 13 further comprising an aluminum salt, 3 de-O-acylated monophosphoryl lipid A or a saponin adjuvant.

Int'l. Appln. No.: PCT/EP00/05841  
Docket No. B45187

17. A composition as claimed in claim 13 wherein the oligonucleotide comprises two CpG dinucleotides.
18. A composition as claimed in claim 13 wherein the CpG oligonucleotide is between 15-45 nucleotides in length.
19. A composition as claimed in claim 13 wherein the CpG oligonucleotide comprises at least one phosphorothioate internucleotide bond.
20. A composition as claimed in claim 13 wherein the oligonucleotide is selected from the group consisting of oligonucleotides designated as WD1001, WD1002, WD1003, WD1004, WD1005, WD1006, and WD1007.
21. A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a composition of claim 13 to a patient.
22. A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a composition of claim 16 to a patient.
23. A method of producing a composition as claimed in claim 13 comprising admixing a malarial antigen and a CpG immunostimulatory oligonucleotide.
24. A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a CpG oligonucleotide followed after a suitable time by an effective amount of a malaria antigen.

- 3 -

Int'l. Appln. No.: PCT/EP00/05841  
Docket No. B45187

REMARKS

The above-identified application is being entered into the National Phase from PCT application no. PCT/EP00/05841.

Applicants have cancelled claims 1-12 and added new claims 13-24 to put the claims in conformity with U.S. practice.

No new matter has been introduced.

Respectfully submitted,



Zoltan Kerekes  
Attorney for Applicants  
Registration No. 38,938

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5024  
Facsimile (610) 270-5090

N:\zk\apps\b45187\Preliminary Amendment.doc



10/018704

B45187

531 Rec'd PCT/ 13 DEC 2001

#### ABSTRACT

A vaccine formulation for the prevention or amelioration of plasmodium infection in humans is provided. The vaccine comprises a malaria antigen, especially a protein which comprises a portion of the CS protein of *P. falciparum* fused in frame via a linear linker to the N-terminal of HBsAg, and an immunostimulatory CpG oligonucleotide. Methods for making the vaccine formulation of the invention are described. Patients may also be treated by pre-administration of the CpG oligonucleotide prior to administration of the malaria antigen.

4pts

WO 01/00231

10/018704

PCT/EP00/05841

10 Rev 1 13 DEC 2001

## VACCINES

The present invention relates to a novel vaccine formulations and their use in medicine, particularly in the prevention of malaria infections. In particular the present invention is concerned with a CpG oligonucleotide and a malarial antigen.

Malaria, is one of the world's major health problems with 2 to 4 million people dying from the disease each year. One of the most acute forms of the disease is caused by the protozoan parasite, Plasmodium falciparum which is responsible for most of the mortality attributable to Malaria.

The life cycle of P. falciparum is complex, requiring two hosts, man and mosquito for completion. The infection of man is initiated by the inoculation of sporozoites in the saliva of an infected mosquito. The sporozoites migrate to the liver and there infect hepatocytes where they differentiate, via the exoerythrocytic intracellular stage, into the merozoite stage which infects red blood cells (RBC) to initiate cyclical replication in the asexual blood stage. The cycle is completed by the differentiation of a number of merozoites in the RBC into sexual stage gametocytes which are ingested by the mosquito, where they develop through a series of stages in the midgut to produce sporozoites which migrate to the salivary gland.

The sporozoite stage of P. falciparum has been identified as a potential target of a malaria vaccine. The major surface protein of the sporozoite is known as circumsporozoite protein (CS Protein). This protein from strain 7G8 has been cloned, expressed and sequenced (Dame et al Science 225 (1984) p593). The protein from strain 7G8 is characterised by having a central immunodominant repeat region comprising a tetrapeptide Asn-Ala-Asn-Pro repeated 37 times but interspersed with four minor repeats Asn-Val-Asp-Pro. In other strains the number of major and minor repeats vary as well as their relative position. This central portion is flanked by an N and C terminal portion composed of non-repetitive amino acid sequences designated as the repeatless portion of the CS protein.



protein. The CS protein may be devoid of the last 12 amino-acids from the C terminal.

In particular there is provided a protein which comprises a portion of the CS protein of *P. falciparum* substantially as corresponding to amino acids 210-398 of *P. falciparum* 7G8 fused in frame via a linear linker to the N-terminal of HBsAg. The linker may comprise a portion of preS2 from HBsAg.

A particularly preferred embodiment is the hybrid protein designated RTS (or RTS,S). This hybrid consists of:

- A methionine-residue, encoded by nucleotides 1059 to 1061, derived from the *Saccharomyces cerevisiae* TDH3 gene sequence. (Musti A.M. et al Gene 1983 25 133-143).
- Three amino acids, Met Ala Pro, derived from a nucleotide sequence (1062 to 1070) created by the cloning procedure used to construct the hybrid gene.
- A stretch of 189 amino acids, encoded by nucleotides 1071 to 1637 representing amino acids 210 to 398 of the circumsporozoite protein (CSP) of *Plasmodium falciparum* strain 7G8 (Dame et al supra).
- An amino acid (Arg) encoded by nucleotides 1638 to 1640, created by the cloning procedure used to construct the hybrid gene.
- Four amino acids, Pro Val Thr Asn, encoded by nucleotides 1641 to 1652, and representing the four carboxy terminal residues of the hepatitis B virus (adw serotype) preS2 protein (9).
- A stretch of 226 amino acids, encoded by nucleotides 1653 to 2330, and specifying the S protein of hepatitis B virus (adw serotype).



International patent application WO 98/ 05355 describes, inter alia, a malaria vaccine based on a combination of Trap and RTS,S.

5 Immunomodulatory oligonucleotides contain unmethylated CpG dinucleotides ("CpG") and are known (WO 96/02555, EP 468520). CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. Historically, it was observed that the DNA fraction of BCG could exert an anti-tumour effect. In further studies, synthetic oligonucleotides derived from BCG gene sequences were  
10 shown to be capable of inducing immunostimulatory effects (both in vitro and in vivo). The authors of these studies concluded that certain palindromic sequences, including a central CG motif, carried this activity. The central role of the CG motif in immunostimulation was later elucidated in a publication by Krieg, Nature 374, p546 1995. Detailed analysis has shown that the CG motif has to be in a certain  
15 sequence context, and that such sequences are common in bacterial DNA but are rare in vertebrate DNA.

It is currently believed that this evolutionary difference allows the vertebrate immune system to detect the presence of bacterial DNA (as occurring during an  
20 infection) leading consequently to the stimulation of the immune system. The immunostimulatory sequence as defined by Krieg is:

Purine Purine CG pyrimidine pyrimidine and where the CG motif is not methylated. In certain combinations of the six nucleotides a palindromic sequence is present.  
25 Several of these motifs, either as repeats of one motif or a combination of different motifs, can be present in the same oligonucleotide. The presence of one or more of these immunostimulatory sequence containing oligonucleotides can activate various immune subsets, including natural killer cells (which produce interferon  $\gamma$  and have cytolytic activity) and macrophages (Wooldrige et al Vol 89 (no. 8), 1977).  
30 Although other unmethylated CpG containing sequences not having this consensus sequence have now been shown to be immunomodulatory.

The present invention provides an improved vaccine formulation comprising a CpG oligonucleotide and a malaria antigen. In particular, RTS,S or RTS,S\* or Trap or immunologically equivalent derivatives thereof.

- 5 Vaccine preparation is generally described in Vaccine Design - The subunit and adjuvant approach (Ed. Powell and Newman) Pharmaceutical Biotechnology Vol. 6 Plenum Press 1995. Encapsulation within liposomes is described by Fullerton, US Patent 4,235,877.
- 10 The preferred oligonucleotides preferably contain two or more CpG motifs separated by six or more nucleotides. The oligonucleotides of the present invention are typically deoxynucleotides. In a preferred embodiment the internucleotide in the oligonucleotide is phosphorodithioate, or more preferably a phosphorodithioate bond, although phosphodiester and other internucleotide bonds are within the scope
- 15 of the invention including oligonucleotides with mixed internucleotide linkages. The sequences preferably contain all phosphorodithioate modified internucleotide linkages. Preferred oligonucleotides have the following sequences:

Oligo (internal designation*)	5'-SEQUENCE-3'	CpG	Thio
WD1001	TCC ATG ACG TTC CTG ACG TT	+	+
WD1002	TCT CCC AGC GTG CGC CAT	+	+
WD1003	ACC GAT AAC GTT GCC GGT GAC G	+	-
WD1004	G*G*G GTC AAC GTT GAG* G*G*G* G*G	+	Mix
WD1005	TCC ATG AGC TTC CTG AGC TT	-	+
WD1006	TCC ATG ACG TTC CTG ACG TT	+	-
WD1007	ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG	+	+
	TCG TCG TTT TGT CGT TTT GTC GTT	+	+

- 20 \* alternatively referred to as WD001-WD007







WO 01/00231

PCT/EP00/05841

WO 9517210, optionally in the presence of a sterol, such as cholesterol as described for example in PCT/EP96/01464. The vaccine of the invention may also comprise monophosphoryl lipid A and derivatives thereof known in the art. A preferred derivative is 3 de-O-acylated monophosphoryl lipid A, described in British Patent  
5 No. 2220211.

Accordingly vaccine formulations of the present invention may additionally comprise other pharmaceutical excipients or immunostimulants. In a preferred embodiment the vaccine formulation additionally comprises an aluminium salt,  
10 preferably aluminium hydroxide.

The present invention will now be described with reference to the following examples:

# 15 **IMMUNOGENICITY STUDIES USING RTS,S FORMULATED WITH CPG OR CPG/ALUM**

## **Evaluation of CpG and CpG/alum in mice**

### *Experiment outline*

20 An immunogenicity study was conducted to evaluate the ability of CpG to serve as an adjuvant for cytotoxic T lymphocyte (CTL) induction. Groups of mice were immunized with RTS,S formulated with CpG oligonucleotide alone or in combination with aluminum hydroxide. After two immunizations spleen cells were examined for the presence of HbsAg-specific effector cells.

25

Table 1: Groups of mice

Group	antigen	adjuvant
1	RTS,S	CpG/alum
2	RTS,S	CpG

WO 01/00231

PCT/EP00/05841

# **Formulation**

*Component batches used:*

COMPONENT	BRAND	BATCH NUMBER	CONCENTRATION (MG/ML)	BUFFER
RTSS		24R51	0.664	P/N 6.8
Al(OH) <sub>3</sub>	Superfos	97A0027	10.380	H <sub>2</sub> O
CpG (WD1001)	Eurogen etech	324255R1	5	H <sub>2</sub> O

## 5 *Formulation process:*

Formulations were prepared 3 days before each injection. All incubations were carried out at room temperature with agitation.

### *CpG/alum group 1 (500µl/dose)*

- 10 RTS, S (8.7µg) and gp120 (8.7µg) were adsorbed on 100µg of Al(OH)<sub>3</sub> or AlPO<sub>4</sub> for 1 hour. The formulation was buffered with a 10-fold concentrated PO<sub>4</sub>/NaCl pH 6.8 solution before addition of 100µg of CpG (WD1001). After 15 min, 50 µg/ml of thiomersal was added as preservative.

### 15 *CpG group 2 (500µl/dose)*

RTS,S (8.7µg) and Gp120(8.7µg) were diluted in PBS pH 6.8 before addition of 100µg of CpG (WD1001). After 5 min, 50 µg/ml of thiomersal was added as preservative.

## 20 **Immunological methods**

Nine Balb/C mice per group received into the hind footpads 100 µl vaccine twice at a two-week-interval. Two weeks later spleen cells were harvested and used to determine the induction of HBsAg-specific CTL.

WO 01/00231

PCT/EP00/05841

For CTL analysis cells were cultured for 7 days in 6-well plates in the presence of 10 µg per ml of synthetic peptide pCMI003 corresponding to an HBsAg CTL epitope (Schirmbeck et al., 1995). At the end of the culture period cells were assessed in duplicate for HBsAg-specific cytolytic activity in standard [<sup>51</sup>Cr]-release assays using control and S-transfected P815 cells. Minimum and maximum release were determined with target cells without effector cells and by the addition of 3 % (v/v) Triton X-100, respectively. Results are expressed as % [<sup>51</sup>Cr]-release (cpm of exp. culture - cpm of spont. release / cpm of max. release - cpm of spont. release).

## 10 Results

Spleen cells from both groups of mice exhibited HBsAg-specific effector cell function in <sup>51</sup>Cr release assays (Figure 1). Untransfected P815 target cells were lysed to a much lesser degree than similar target cells expressing the HBV s gene. Lysis of the target cells diminished with decreasing effector to target cell ratios.

15

## Conclusions

Immunization with RTS,S in combination with CpG or CpG/alum induces HBsAg-specific CTL in mice.

## 20 EVALUATION OF CPG AND CPG/ALUM IN RHESUS MONKEYS

### *Experiment outline*

An immunogenicity study was conducted to evaluate the adjuvant effect of CpG in non-human primates. Groups of five monkeys were immunized twice with RTS,S in combination with CpG or CpG/alum. After the second immunization the immune response of the animals was assessed. Antibodies to HBsAg and lymphoproliferative as well as cytokine responses were evaluated.

30

Table 2. Groups of monkeys

Group	antigen	adjuvant
1	RTS,S	CpG/alum
2	RTS,S	CpG

### Formulation

*Component batches used:*

5

COMPONENT	BRAND	BATCH NUMBER	CONCENTRATION (MG/ML)	Buffer
RTS,S		ERTS1X058	1.372	P/N 6.8
Al(OH) <sub>3</sub>	Superfos	96A0089	10.380	H <sub>2</sub> O
CpG		WD1001	5	H <sub>2</sub> O

*Formulation process:*

Formulations were prepared one day before each injection. All incubations were carried out at room temperature with agitation.

#### 10 *CpG/alum group 1 (500µl/dose)*

RTS,S (50µg) was adsorbed on 500µg of Al(OH)<sub>3</sub> for 1 hour. The formulation was buffered with a 10-fold concentrated PO<sub>4</sub>/NaCl pH 6.8 solution before addition of 500µg of CpG (WD1001). After 15 min, 50 µg/ml of thiomersal was added as preservative.

15

H<sub>2</sub>O + Al(OH)<sub>3</sub> + RTS,S-1H-10xPN-15m-CpG-15m-Thio

#### **CpG group 2 (500µl/dose)**

RTS,S (50µg) was diluted in PO<sub>4</sub>/NaCl buffer pH 6.8 before addition of 500µg of CpG WD1001. After 15 min, 50 µg/ml of thiomersal was added as preservative.

20

H<sub>2</sub>O + RTSS + 10xPN-15m-CpG-15m-Thio

### Immunological methods

Five rhesus monkeys (*Macaca mulatta*) per group were immunized twice intramuscularly with 500  $\mu$ l of vaccine at a four-week-interval. Sera and peripheral  
5 blood mononuclear cells (PBMC) were taken at several occasions.

HBsAg-specific antibodies in monkey sera were determined in a radio immuno assay (RIA, Abbott) according to the manufacturer's instructions.

10 Lymphoproliferation was assessed by using density gradient-purified PBMC from immunized rhesus monkeys. Cells were seeded in quadruplicates at  $1 \times 10^5$  in 100  $\mu$ l RPMI/5 % FCS per well in round bottom 96 well plates. Then another 100  $\mu$ l of medium alone or containing soluble RTS,S (10  $\mu$ g/ml) were added and parallel cultures were incubated for 48 hrs. Thereafter, 100  $\mu$ l culture supernatant were  
15 replaced by fresh medium containing 1  $\mu$ Ci [ $^3$ H]-thymidine. After 16 hrs cells were harvested onto filter plates and incorporated radioactivity was determined in a  $\beta$ -counter. Results are expressed in cpm and in stimulation indices (SI, = cpm antigen-containing cultures/cpm medium alone cultures), SI greater than 3 are considered as a positive response.

20

Flat bottom 96 well plates were prepared by coating an IFN- $\gamma$ -specific capture antibody in 50  $\mu$ l PBS for 4 hrs at 37 °C. The plates were washed three times and PBMC were seeded similar to lymphoproliferation assays. After 48 hrs of culture the plates were washed thrice with PBS/0.05 % Tween 20 and 50  $\mu$ l of biotinylated  
25 secondary IFN- $\gamma$ -specific antibody diluted in PBS/Tween/1 % FCS were added for 2 hrs. The plates were washed again and a gold-conjugated  $\alpha$ -biotin antibody was incubated for 1 hr. After additional washings the ELIspots were visualized by using a silver enhancing kit (50  $\mu$ l per well). The reaction was stopped after approx. 30 min by adding deionized water. Cytokine-secreting cells were enumerated by  
30 microscopic examination.

## Results

Analysis of HBsAg-specific antibodies in sera of the monkeys revealed that all animals in the two groups had developed specific immune responses (Figure 2). Some responses were detectable already after one immunization. Interestingly, these responses were boosted by the second immunization only in group 1, while titers in group 2 remained more or less constant.

Induction of specific lymphoproliferation by immunization with RTS,S in combination with CpG or CpG/alum was evaluated before immunization and 6 days post secondary immunization. All 10 animals did not exhibit any specific lymphoproliferation ( $SI > 3$ ) at the study start (data not shown). In contrast, all animals in group 1 possessed strong lymphoproliferative responses 6 days post boost immunization (Figure 3). All animals from group 2 did, however, remain negative in this analysis.

The presence of RTS,S-specific IFN- $\gamma$ -secreting cells was investigated in all monkeys before immunization and 6 days after the second dose. IFN- $\gamma$ -secreting cells could not be evaluated from pre-immunization samples due to technical difficulties. However, such cells were detectable after secondary immunization (Figure 4). All animals in group 1 exhibited a positive response, while only one animal in group 2 was positive.

## Conclusions

Immunization with RTS,S in combination with CpG induces immune responses in non-human primates. After two immunizations CpG alone induces low level HBsAg-specific antibodies, while CpG combined with alum induces high titer antibodies as well as vigorous lymphoproliferative and IFN- $\gamma$  responses.





**Claims:**

1. A vaccine formulation comprising a malaria antigen and an immunostimulatory  
5 CpG oligonucleotide.
2. A vaccine as claimed in claim 1 wherein the antigen is selected from the group,  
RTS, RTS\*, TRAP or immunologically equivalent derivatives thereof.
3. A vaccine as claimed in claim 1 or 2 wherein the vaccine comprises TRAP or  
immunologically equivalent derivative and one of RTS or RTS\*.
- 10 4. A vaccine formulation as claimed herein additionally comprising an aluminium  
salt, 3 de-O-acylated monophosphoryl lipid A or a saponin adjuvant.
5. A vaccine as claimed herein wherein the oligonucleotide comprises two CpG  
dinucleotides.
6. A vaccine as claimed herein wherein the CpG oligonucleotide is between 15-45  
15 nucleotides in length.
7. A vaccine as claimed herein wherein the CpG oligonucleotide comprises at least  
one phosphorothioate internucleotide bond.
8. A vaccine as claimed herein wherein the oligonucleotide is selected from the  
group:

20

Oligo (internal designation)	5'-SEQUENCE-3'	CpG	Thio
WD1001	TCC ATG ACG TTC CTG ACG TT	+	+
WD1002	TCT CCC AGC GTG CGC CAT	+	+
WD1003	ACC GAT AAC GTT GCC GGT GAC G	+	-
WD1004	G*G*G GTC AAC GTT GAG* G*G*G* G*G	+	Mix
WD1005	TCC ATG AGC TTC CTG AGC TT	-	+
WD1006	TCC ATG ACG TTC CTG ACG TT	+	-
WD1007	ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG	+	+
	TCG TCG TTT TGT CGT TTT GTC GTT	+	+

9. A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a vaccine of any one of claims 1 to 8 to a patient.
- 5 10. A vaccine as claimed herein for use as a medicament.
11. A method of producing a vaccine as claimed in any one of claims 1 to 8 comprising admixing a malarial antigen and a CpG immunostimulatory oligonucleotide.
- 10 12. A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a CpG oligonucleotide followed after a suitable time by an effective amount of a malaria antigen.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number  
**WO 01/00231 A3**



- (51) International Patent Classification<sup>7</sup>: **A61K 39/39**,  
A61P 33/06 // (A61K 39/39, 39:005)
- (21) International Application Number: **PCT/EP00/05841**
- (22) International Filing Date: **23 June 2000 (23.06.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
9915204.3                      29 June 1999 (29.06.1999)    **GB**
- (71) Applicant (*for all designated States except US*):  
**SMITHKLINE BEECHAM BIOLOGICALS S.A.**  
[BE/BE]; Rue de L'Institut 89, B-1330 Rixensart (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **COHEN, Joseph**  
[US/BE]; SmithKline Beecham Biologicals S.A., Rue de  
l'Institut 89, B-1330 Rixensart (BE). **GARCON, Nathalie**  
[FR/BE]; SmithKline Beecham Biologicals S.A., Rue  
de l'Institut 89, B-1330 Rixensart (BE). **VOSS, Gerald**  
[DE/BE]; SmithKline Beecham Biologicals S.A., Rue de  
l'Institut 89, B-1330 Rixensart (BE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *With international search report.*
- (88) Date of publication of the international search report:  
**5 July 2001**
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **USE OF CPG AS AN ADJUVANT FOR MALARIA VACCINE**

(57) Abstract: A vaccine formulation for the prevention or amelioration of plasmodium infection in humans is provided. The vaccine comprises a malaria antigen, especially a protein which comprises a portion of the CS protein of *P. falciparum* fused in frame via a linear linker to the N-terminal of HBsAg, and an immunostimulatory CpG oligonucleotide. Methods for making the vaccine formulation of the invention are described. Patients may also be treated by pre-administration of the CpG oligonucleotide prior to administration of the malaria antigen.

**WO 01/00231 A3**

1 / 4



**Fig 1:**

2/4

**Fig 2:****Titer anti-HBs (m UI/ml-RIA)**

		d -12	average	14 d post I	average	7 d post II	average	28 d post II	average
Group 1	N5V	<1		115		921		1352	
	I055	<1		76		6424		1112	
	R441	<1	<b>8</b>	222	<b>193</b>	369	<b>1907</b>	431	<b>888</b>
	BXJ	8		121		862		546	
	CPJ	<1		430		960		997	
Group 2	NJ5	<1		<1		17		11	
	X006	4		4		51		37	
	I041	<1	<b>4</b>	11	<b>29</b>	42	<b>71</b>	5	<b>35</b>
	R361	<1		2		68		62	
	BBE	3		100		175		61	

Fig. 2a




Fig. 2b

	-12	0	14	28	34	56
Group 1	8	193	1907	888		
Group 2	4	29	71	35		

Fig. 2c

Fig. 3:




Fig. 3a




Fig. 3c




Fig. 3b




Fig. 3d

**Fig 4:**

<b>Group 1</b>					
	<b>N5V</b>	<b>I055</b>	<b>R441</b>	<b>BXJ</b>	<b>CPJ</b>
<b>RTS,S</b>	+	++	++	++	++
Unstimulated cells	-	-	-	-	-
					<b>5/5</b>

<b>Group 2</b>					
	<b>NJ5</b>	<b>X006</b>	<b>I041</b>	<b>R361</b>	<b>BBE</b>
<b>RTS,S</b>	-	+	+++	+	-
Unstimulated cells	-	+	+	+	-
					<b>1/5</b>

Docket No.: B45187

PCT/EP00/05841

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

VACCINE

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 23 June 2000 as Serial No. PCT/EP00/05841  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9915204.3	Great Britain	29 June 1999	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------





I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.


Address all correspondence and telephone calls to Zoltan Kerekes , SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-5024.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00 Full Name of Inventor: Joseph COHEN,  
 Inventor's Signature:  Date: 7/12/2001  
 Residence: RIXENSART, BELGIUM BEX  
 Citizenship: AMERICAN  
 Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

2-00 Full Name of Inventor: Nathalie GARCON  
 Inventor's Signature:  Date: 10/12/01  
 Residence: RIXENSART, BELGIUM BEX  
 Citizenship: FRENCH  
 Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

3-00  
Full Name of Inventor: Gerald VOSS

Inventor's Signature: 

Date: 7.12.2001

Residence:

RIXENSART, BELGIUM

DEX

Citizenship:

GERMAN

Post Office Address:

SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

SEQUENCE LISTING

<110> Cohen, Joe  
Garcon, Nathalie  
Voss, Gerald

<120> Vaccine

<130> B45187

<140> 10/018,704

<141> 2001-12-13

<150> PCT/EP00/05841

<151> 2000-06-23

<150> GB 9915204.3

<151> 1999-06-29

<160> 7

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide containing a CpG motif

<400> 1

tccatgacgt tctgacgtt

20

<210> 2

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide containing a CpG motif

<400> 2  
tctcccagcg tgcgcat 18

<210> 3  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide containing a CpG motif

<400> 3  
accgataacg ttgccggtga cg 22

<210> 4  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide containing a CpG motif  
Nucleotides 1, 2, 15, 16, 17, 18 and 19 have  
linkages with a thioate modification

<400> 4  
ggggtcaacg ttgagggggg 20

<210> 5  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide containing a GpC motif

<400> 5  
tccatgagct tcctgagctt 20

<210> 6  
<211> 20  
<212> DNA  
<213> Artificial Sequence

[illegible] $\langle 220 \rangle$ 

<223> Oligonucleotide containing a CpG motif

<400> 6

tccatgacgt tcctgacgtt

20

<210> 7

<211> 54

<212> DNA

<213> Artificial Sequence

 $\langle 220 \rangle$ 

<223> Oligonucleotide containing a CpG motif

<400> 7

accgatgacg tcgccggtga cggcaccacg tcgtcgtttt gtcgttttgt cgtt

54

10018704 1030702

10/018704

531 Rec'd PCT/ 13 DEC 2001

SEQUENCE LISTING

<110> Cohen, Joe  
Garcon, Nathalie  
Voss, Gerald

<120> Vaccine

<130> B45187

<140> PCT/EP00/05841

<141> 2000-06-23

<150> GB 9915204.3

<151> 1999-06-29

<160> 7

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 1

tccatgacgt tcctgacgtt

20

<210> 2

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 2

tctcccagcg tgcgcat

18

<210> 3  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Oligonucleotide

<400> 3  
 accgataacg ttgccggtga cg 22

<210> 4  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Oligonucleotide  
 Nucleotides 1, 2, 15, 16, 17, 18 and 19 have  
 linkages with a thioate modification

<400> 4  
 ggggtcaacg ttgagggggg 20

<210> 5  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Oligonucleotide

<400> 5  
 tccatgagct tcctgagctt 20

<210> 6  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Oligonucleotide

<400> 6

tccatgacgt tcctgacgtt

20

<210> 7

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 7

accgatgacg tcgccggtga cggcaccacg tcgtcgtttt gtcgttttgt cggt

54